

Wellnex's Paracetamol Soft Gel Liquid Analgesic receives UK approval

Key Highlights

- *Wellnex's TGA registered paracetamol soft gel liquid analgesic receives UK regulatory approval for sales in the UK market.*
- *Wellnex will supply one of the world's largest independent consumer healthcare companies Haleon with this innovative product for use in one of the world's most trusted pain relief brands, Panadol, with sales to commence in FY25.*
- *The expansion into this important European market builds on the launch of the Australian market which commenced in FY23.*
- *The arrangement with Haleon is a testament and validation of Wellnex's business model of being the owner of healthcare brands and IP for the Australian and global markets.*

Wellnex Life Limited (**Wellnex, WNX or Company**) (ASX:WNX), a leading consumer healthcare business, is pleased to announce that Haleon UK has received regulatory approval for the sale of the innovative paracetamol soft gel liquid analgesic for the United Kingdom market.

As announced on 29 June 2023, Wellnex and Haleon agreed to extend its existing arrangement for the Australian market, by increasing the product offerings and territories to take advantage of the unique and innovative products Wellnex has received TGA approval for in the Australian market. After an extended period of supporting Haleon on the UK approval of the paracetamol soft gel liquid analgesic, it is anticipated that first sales are to commence in FY 25.

Wellnex has been supplying this innovative product to Haleon for the Australian market for one of the worlds most trusted pain relief brands – Panadol.

Haleon is a world-leading consumer healthcare company that owns brands including Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil.

This significant step in achieving regulatory approval in an important market in the UK and working with one of world's largest consumer healthcare companies highlights the benefits of Wellnex's business model of identifying innovative healthcare products enabling Wellnex to secure valuable agreements with leading partners, such as Haleon.

Zack Bozinovski, Director of Wellnex, said *"the UK regulator approval of our TGA registered paracetamol soft gel liquid analgesic for one of Europe's largest markets is*

an important milestone for the Company and is the first step in the planned roll out of additional products and territories moving forward. To be able to partner with a global leader such as Haleon, after a successful launch in Australia is a testament to the Wellnex business model."

- ENDS -

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX).

For further information, please contact:

George Karafotias – Chief Executive Officer

P: +61 3 8399 9419

E: George.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/